Nike’s appointment of a CFO coming from pharma and retail suggests that capital allocation discipline now ranks above sector experience as the brand executes its Sport Offense growth model.
Nike has named David M. Denton as Executive Vice President and Chief Financial Officer, effective August 17. Incumbent CFO Matthew Friend will step down on the same date and remain with the company through September 4 to support the transition. Friend will participate in Nike’s fourth quarter fiscal 2026 earnings call on June 30, as scheduled.
Denton arrives from Pfizer, where he has served as CFO and Executive Vice President since May 2022. Before that, he spent four years at Lowe’s Companies as CFO, overseeing finance, strategy, and enterprise functions during a period of operational transformation. Earlier in his career, he held the CFO role at CVS Health Corporation for two decades, where he helped reshape the company into a diversified health services organization. He also brings board-level experience, having served as a director at Haleon and Tapestry, and is expected to join the board of Honeywell Aerospace following its planned spin-off.
Denton’s career has been built entirely outside the sporting goods industry. His operating background spans healthcare, pharmacy retail, and home improvement: sectors defined by high transaction volume, complex supply chains, and sustained pressure on margins.
The announcement also included a brief financial update: Nike’s fourth quarter fiscal 2026 results, due June 30, are expected to benefit from tariff refunds not included in previous guidance. Excluding that one-time item, results are expected to be broadly in line with prior guidance
